Chardan Capital maintains Ocular Therapeutix Buy and $23 price target
Chardan Capital maintained its Buy rating on Ocular Therapeutix and kept a $23.00/share price target, reported by Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.